A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(51 sites)

United States

Alaska Oncology & Hematology, LLC, Anchorage, Alaska

Community Cancer Institute (CCI), Clovis, California

Providence Medical Foundation, Fullerton, California

Los Angeles Cancer Network, Glendale, California

Valkyrie Clinical Trials, Los Angeles, California